{"entity":{"id":"eltrombopag","kind":"drug","name":"Eltrombopag","aka":["Eltrombopag Olamine","SB-497115"],"tldr":"Eltrombopag is a daily tablet that raises platelet counts by stimulating the bone marrow; it is approved for immune thrombocytopenia and severe aplastic anaemia, and haematologists also use it when low platelets complicate blood cancers and their treatment.","summary":"Eltrombopag is an oral thrombopoietin receptor agonist first approved in the United States in 2008 for chronic immune thrombocytopenia (ITP) that has not responded to steroids, immunoglobulins or splenectomy. Its label also covers thrombocytopenia in hepatitis C to allow interferon treatment and severe aplastic anaemia, a bone marrow failure that sits alongside myelodysplastic syndromes in haematology clinics. It is not approved for chemotherapy-induced thrombocytopenia or for low platelets in leukaemia or myelodysplasia, though it has been studied in both and is used off label. Liver toxicity and a possible increase in marrow fibrosis or blast counts are the main cautions.","status":"established","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Eltrombopag","links":[{"label":"Label (DailyMed)","url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=eltrombopag"},{"label":"Drugs@FDA NDA 022291","url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022291"}],"tags":["gap-fill","supportive-care"],"related":[],"cancers":["aml","mds"],"sections":[],"technologies":["supportive-care"],"targets":[],"drugs":["romiplostim"],"companies":["novartis"],"institutions":[],"pathways":[],"terms":["thrombocytopenia"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"brand":"Promacta / Revolade","modality":"Oral thrombopoietin receptor agonist","mechanism":"A small molecule that binds the transmembrane part of the thrombopoietin receptor (MPL) on megakaryocytes and their precursors, driving them to make platelets.","approvals":[{"region":"US","year":2008,"indication":"Chronic immune thrombocytopenia with insufficient response to corticosteroids, immunoglobulins or splenectomy","note":"Later extended to thrombocytopenia in chronic hepatitis C and to severe aplastic anaemia"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/eltrombopag/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"mds","kind":"cancer","name":"Myelodysplastic syndromes / neoplasms (MDS)","route":"/cancers/mds/"}],"section":[{"id":"supportive-care","kind":"section","name":"Supportive Care & Survivorship","route":"/fronts/supportive-care/"}],"drug":[{"id":"romiplostim","kind":"drug","name":"Romiplostim","route":"/drugs/romiplostim/"}],"company":[{"id":"novartis","kind":"company","name":"Novartis","route":"/companies/novartis/"}],"term":[{"id":"thrombocytopenia","kind":"term","name":"Thrombocytopenia","route":"/terms/thrombocytopenia/"}]}}